Target type: biologicalprocess
Any process that increases the rate, frequency or extent of a vitamin D biosynthetic process. Vitamin D biosynthesis is the chemical reactions and pathways resulting in the formation of vitamin D, any of a group of related, fat-soluble compounds that are derived from delta-5,7 steroids and play a central role in calcium metabolism. Specific forms of vitamin D include calciferol (ergocalciferol; vitamin D2) and cholecalciferol (calciol; vitamin D3). [CHEBI:27300, GOC:BHF, GOC:mah, ISBN:0471331309]
Positive regulation of vitamin D biosynthesis involves a complex interplay of factors, primarily centered around the conversion of 7-dehydrocholesterol (7-DHC) to cholecalciferol (vitamin D3) in the skin upon exposure to UVB radiation. This process is tightly regulated to ensure optimal vitamin D production while preventing excessive accumulation.
**Key Steps and Regulators:**
1. **UVB Radiation:** UVB radiation from sunlight triggers the conversion of 7-DHC to previtamin D3 in the skin. This is the initial and crucial step in vitamin D biosynthesis.
2. **Isomerization:** Previtamin D3 undergoes a thermal isomerization process, converting to vitamin D3 (cholecalciferol) over a few hours.
3. **Transport:** Vitamin D3 is then transported to the liver via binding proteins.
4. **Hydroxylation:** In the liver, vitamin D3 undergoes the first hydroxylation reaction, catalyzed by the enzyme 25-hydroxylase (CYP2R1), producing calcidiol (25-hydroxyvitamin D).
5. **Regulation in the Liver:** The level of calcidiol in the blood is tightly regulated by various factors, including dietary intake of vitamin D, UVB exposure, and circulating levels of parathyroid hormone (PTH).
6. **Further Hydroxylation:** Calcidiol is further hydroxylated in the kidneys by 1α-hydroxylase (CYP27B1), producing the biologically active form of vitamin D, calcitriol (1,25-dihydroxyvitamin D).
7. **Regulation in the Kidneys:** 1α-hydroxylase activity is influenced by circulating levels of calcium, PTH, and calcitriol itself. This negative feedback loop ensures that calcitriol levels are maintained within a specific range.
**Factors Influencing Positive Regulation:**
* **UVB Exposure:** Sufficient UVB radiation is essential for initiating the conversion of 7-DHC to vitamin D3.
* **Dietary Vitamin D Intake:** Consuming vitamin D-rich foods, such as fatty fish, eggs, and fortified milk, can supplement UVB exposure.
* **Parathyroid Hormone (PTH):** PTH stimulates 1α-hydroxylase activity in the kidneys, increasing calcitriol production.
* **Calcium Levels:** Low calcium levels stimulate PTH release, indirectly promoting calcitriol production.
* **Other Hormones:** Hormones like estrogen and growth hormone may also influence vitamin D synthesis and metabolism.
**Factors Influencing Negative Regulation:**
* **Vitamin D Deficiency:** Low vitamin D levels trigger a cascade of events aimed at increasing calcitriol production, including increased PTH secretion.
* **Excess Vitamin D:** High levels of vitamin D can inhibit further production, primarily by suppressing the activity of 1α-hydroxylase.
**Overall, positive regulation of vitamin D biosynthesis involves a coordinated effort of various factors, including UVB radiation, dietary intake, hormonal signals, and feedback mechanisms. This complex process ensures that adequate levels of active vitamin D are maintained for maintaining calcium homeostasis and supporting overall health.**'
"
Protein | Definition | Taxonomy |
---|---|---|
Tumor necrosis factor | A tumor necrosis factor that is encoded in the genome of human. [PRO:DNx] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
mesalamine | mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position. Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed) | amino acid; aromatic amine; monocarboxylic acid; monohydroxybenzoic acid; phenols | non-steroidal anti-inflammatory drug |
way 151693 | |||
pentoxifylline | oxopurine | ||
4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone | 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone: Inhibitor of phosphodiesterases. | methoxybenzenes | |
rolipram | pyrrolidin-2-ones | antidepressant; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor | |
sulfasalazine | sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position. Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907) | ||
bergenin | bergenin: RN refers to (2R-(2alpha,3beta,4alpha,4aalpha,10bbeta))-isomer; structure | trihydroxybenzoic acid | metabolite |
marimastat | marimastat : A secondary carboxamide resulting from the foraml condensation of the carboxy group of (2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoic acid with the alpha-amino group of N,3-dimethyl-L-valinamide. marimastat: a matrix metalloproteinase inhibitor active in patients with advanced carcinoma of the pancreas, prostate, or ovary | hydroxamic acid; secondary carboxamide | antineoplastic agent; matrix metalloproteinase inhibitor |
birb 796 | aromatic ether; morpholines; naphthalenes; pyrazoles; ureas | EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; immunomodulator | |
ganoderic acid a | triterpenoid | ||
ganoderiol f | ganoderiol F: a ganoderma triterpene from Ganoderma amboinense; structure in first source | triterpenoid | |
1-(phenylmethyl)benzimidazole | benzimidazoles | ||
luteolin-7-glucoside | luteolin 7-O-beta-D-glucoside : A glycosyloxyflavone that is luteolin substituted by a beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage. luteolin-7-glucoside: has both antiasthmatic and antineoplastic activities; has 3C protease inhibitory activity; isolated from Ligustrum lucidum | beta-D-glucoside; glycosyloxyflavone; monosaccharide derivative; trihydroxyflavone | antioxidant; plant metabolite |
apigetrin | apigenin 7-O-beta-D-glucoside : A glycosyloxyflavone that is apigenin substituted by a beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage. apigetrin: structure given in first source | beta-D-glucoside; dihydroxyflavone; glycosyloxyflavone; monosaccharide derivative | antibacterial agent; metabolite; non-steroidal anti-inflammatory drug |
calycosin-7-o-beta-d-glucopyranoside | calycosin-7-O-beta-D-glucoside : A glycosyloxyisoflavone that is calycosin substituted by a beta-D-glucopyranosyl residue at position at 7 via a glycosidic linkage. calycosin-7-O-beta-D-glucoside: from Radix Astragali | 4'-methoxyisoflavones; 7-hydroxyisoflavones 7-O-beta-D-glucoside; hydroxyisoflavone; monosaccharide derivative | |
spd-304 | SPD-304: structure in first source | ||
ganoderic acid f | ganoderic acid F: isolated from Ganoderma lucidum; structure in first source | triterpenoid | |
ganoderic acid c2 | ganoderic acid C2: from the fruiting body of Ganoderma; structure in first source | triterpenoid |